• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate

April 6, 2021 By Sean Whooley

Seelos Therapeutics AptarGroup Aptar PharmaSeelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device.

The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device to deliver Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD).

Under the agreement, Seelos garners certain rights to add other undisclosed indications to the partnership for use with Aptar’s Bidose system, according to a news release.

Aptar’s Bidose system has FDA approval and authorization from the European Medicines Agency to deliver intranasal therapeutics like SLS-002, where a precise delivery of active CNS drug formulations is required.

Seelos has completed part one, a 16-patient, open-label cohort, of its proof-of-concept study using the Aptar Bidose system to deliver 90mg of SLS-002 to patients who are imminently suicidal. This precedes part two, which is a registrational, double-blind, placebo-controlled trial.

The company expects to release open-label data in the second quarter of 2021 once data from part one is analyzed, as the final patient in that cohort completed their part of the study on March 30.

“Aptar is a world-class organization and has been an integral partner for our intranasal ketamine program since our inception,” Seelos chairman & CEO Raj Mehra said in the release. “This partnership strengthens the collaboration between Seelos and Aptar and further protects the SLS-002 franchise.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Neurological Tagged With: aptarpharma, Seelos Therapeutics

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS